Gastrointestinal tract (lower) cancers - recognition and referral
Exam Tips
- In symptomatic adults, FIT is a triage tool, not a rule-out test: persistent concerning symptoms require safety-netting and possible referral even with FIT <10 micrograms Hb/g.
- Memorise key direct-referral findings: rectal mass, unexplained anal mass, unexplained anal ulceration, or occult faecal blood should trigger urgent cancer-pathway thinking without waiting for routine pathways.
- Age-pattern clues: unexplained rectal bleeding/abdominal pain/weight loss in >=50 years lowers threshold for FIT and urgent investigation; in <50 years, combinations of bleeding with abdominal pain or weight loss remain high risk.
- In OSCEs, explicitly communicate urgency, expected timelines, and that most urgent referrals do not ultimately prove cancer while still justifying rapid assessment.
Definition
Lower gastrointestinal tract cancers in this referral context mainly include colorectal adenocarcinoma and anal squamous cell carcinoma presenting in primary care with red-flag bowel, bleeding, pain, weight-loss or anaemia features. The clinical priority is early recognition, risk stratification with quantitative FIT where indicated, and rapid referral through the suspected cancer pathway rather than delayed symptom-based treatment.
Pathophysiology
Most colorectal cancers arise through stepwise malignant transformation of colonic epithelium (typically adenoma-to-carcinoma) driven by cumulative genetic and epigenetic change, with progressive invasion through bowel wall and potential lymphatic/haematogenous spread (commonly to liver and lung). Right-sided disease more often presents with occult blood loss and iron-deficiency anaemia, whereas left-sided/rectal disease more often causes visible rectal bleeding or altered bowel habit due to luminal narrowing. Anal cancer is usually squamous cell carcinoma, frequently linked to persistent high-risk HPV infection with dysplastic progression in the anal canal epithelium. See Figure: adenoma-carcinoma sequence and colorectal wall invasion in a standard GI pathology textbook.
Risk Factors
- Increasing age (especially >=50 years for colorectal cancer symptom thresholds)
- Personal or family history of colorectal neoplasia
- Inflammatory bowel disease (long-standing colitis)
- Lifestyle factors: obesity, low-fibre/high-processed-meat diet, smoking, alcohol
- Inherited syndromes (for example Lynch syndrome, FAP)
- Persistent high-risk HPV exposure and immunosuppression (anal squamous cancer risk)
Clinical Features
Symptoms
- Change in bowel habit (diarrhoea, constipation, or mixed pattern)
- Rectal bleeding (with or without abdominal pain/weight loss depending on age)
- Unexplained weight loss
- Unexplained abdominal pain
- Appetite loss
- Anal pain or tenesmus (particularly for anal cancer)
Signs
- Iron-deficiency anaemia (or anaemia in older adults even if non-iron-deficient)
- Palpable abdominal mass
- Rectal mass on examination
- Unexplained anal mass
- Unexplained anal ulceration
- Features of advanced disease (cachexia, hepatomegaly, bowel obstruction signs)
Investigations
Management
Lifestyle Modifications
- Safety-net clearly: if FIT not returned or FIT <10 but symptoms persist/progress, reassess promptly and do not delay referral when clinical concern remains high.
- Explain suspected cancer referral pathway and timelines (urgent action and expected 28-day diagnosis/rule-out target after urgent GP referral).
- Provide practical support to improve FIT sample return (written instructions, accessibility help, carer support where appropriate).
- Communicate alternative benign diagnoses while maintaining urgency to reduce anxiety and improve engagement.
Pharmacological Treatment
Supportive treatment for iron-deficiency anaemia while awaiting specialist work-up
- Ferrous sulfate 200 mg oral once daily (about 65 mg elemental iron) as first-line oral iron
- Ferrous fumarate 210 mg oral once daily (about 68 mg elemental iron) as alternative
- Ferrous gluconate 300 mg oral once daily (about 35 mg elemental iron) if poorer tolerance
Use only as supportive care and do not delay urgent cancer referral. Counsel regarding GI adverse effects (constipation, abdominal discomfort, dark stools) and interactions (reduced absorption with antacids/calcium; separate dosing). Avoid oral iron in significant iron-overload states; consider urgent specialist input if severe symptomatic anaemia or intolerance/non-response.
Surgical / Interventional
- No primary-care surgical treatment at recognition stage; definitive management follows specialist staging.
- Potential specialist treatments after diagnosis include colorectal resection (segmental colectomy/anterior resection), local excision in selected early lesions, and oncological chemoradiotherapy for many anal squamous cancers.
Complications
- Large bowel obstruction
- Bowel perforation and peritonitis
- Chronic bleeding causing iron-deficiency anaemia
- Metastatic spread (especially liver and lung in colorectal cancer)
- Venous thromboembolism
- Local invasion causing pain, tenesmus, or fistulation (site dependent)
Prognosis
UK data indicate approximately 60% 5-year survival for both colorectal and anal cancers overall, but outcomes vary strongly by stage at diagnosis. Earlier recognition and timely referral from primary care improve the chance of curative treatment.
Sources & References
✅NICE Guidelines(1)
📖Textbook References(10)
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 322)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 682, 683)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 682)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 682, 683)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 682)[context]
- [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 109, 110)[context]
- [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 373)[context]
- [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 372, 373)[context]
- [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 373, 374)[context]
- [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 110)[context]